(Total Views: 550)
Posted On: 05/20/2020 3:04:30 PM
Post# of 148908
Blafarm,
Thank you. Great to see Christine
and, of course, hear from Nader 
I agree with him wholeheartedly, the numbers MUST transfer into clinical outcomes. I will be really surprised if we don't crush the primary end point (Nader's words).
This will be the direct result of a little OTC company crushing the FDA primary end-point. Please remember, currently there is no SOC for mild-to-moderate in COVID.
I wouldn't be in the FDA shoes when they see the p-number with several 0's after the period and have to decide what to do next.
Thank you. Great to see Christine
and, of course, hear from Nader Quote:
This data is really amazing. So, why do we think we are going to crush the primary endpoint ? in our opinion is because the patients that we took in Montefiore Hospital we got their blood samples, day 0, 3, 7, 14th and, if they stayed alive, even longer, that blood samples, all of them, showed immunological benefit RANTES drop which is ccl5 which relates to ccr5 so, we have data, we have data, data that shows that we are going to be successful with this trial, and we excited to get to the end of May hopefully we get to 75 and two weeks later we will let the world know the results.
I agree with him wholeheartedly, the numbers MUST transfer into clinical outcomes. I will be really surprised if we don't crush the primary end point (Nader's words).
Quote:
This company in my opinion is going to have a great deal of appreciation on the value
This will be the direct result of a little OTC company crushing the FDA primary end-point. Please remember, currently there is no SOC for mild-to-moderate in COVID.
I wouldn't be in the FDA shoes when they see the p-number with several 0's after the period and have to decide what to do next.
(6)
(0)Scroll down for more posts ▼
